• ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial 

      Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika; Becker, Richard C; Bertilson, Maria; Budaj, Andrzej; Cornel, Jan H; Himmelmann, Anders; James, Stefan K; Siegbahn, Agneta; Storey, Robert F; Kontny, Frederic; Aukrust, Pål; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-11-29)
      <p><i>Background and aims - </i>Activated leukocyte cell adhesion molecule (ALCAM) is upregulated during inflammation and involved in transmigration of leukocytes and T-cell activation. We hypothesized that ALCAM might be associated with recurrent events in patients with acute coronary syndromes (ACS). <p><i>Methods - </i>ALCAM was measured in serum obtained on admission, at discharge, 1 month and ...
    • Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes: Insights from the PLATO (Platelet Inhibition and Patient Outcomes) trial 

      Ueland, Thor; Åkerblom, Axel; Ghukasyan, Tatevik; Michelsen, Annika; Aukrust, Pål; Becker, Richard C.; Bertilsson, Maria; Himmelmann, Anders; James, Stefan K.; Siegbahn, Agneta; Storey, Robert F.; Kontny, Frederic; Wallentin, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-01-12)
      Background: <br>Elevated levels of osteoprotegerin, a secreted tumor necrosis factor–related molecule, might be associated with adverse outcomes in patients with coronary artery disease. We measured plasma osteoprotegerin concentrations on hospital admission, at discharge, and at 1 and 6 months after discharge in a predefined subset (n=5135) of patients with acute coronary syndromes in the PLATO ...